Respiratory Treatments Poster June2022v1
Respiratory Treatments Poster June2022v1
Respiratory Treatments Poster June2022v1
NDICATOR = GENERIC AVAILABLE DISEASE STATES: = ASTHMA = COPD Allergy & Asthma Network is a national nonprofit
organization dedicated to ending needless death
AllergyAsthmaNetwork.org and suffering due to asthma, allergies and related
ONISTasBcouRghOingN
800.878.4403
IST BRONCHO
and research.
G B E T A -A G 2
DILATORS
RT-eAs inCaTirwIaN
2 h , w he ezing and shortne of breath for 3-6 hours muscles in airways and offer lasting r
elief of symptoms suc
SHiO symptoms suc h as coughing, w
quick relief of heezing and s rela
ys and offer Proventil HFA Ventolin ®
® Xopenex Serevent®
hortness of
breath for x tight
ght muscl
relax t ProAir HFA HFA® a t least 12
hours
ProAir® 90 mcg Diskus® Striverdi ®
RespiClick® albuterol 90 mcg 45 mcg
50 mcg
ProAir® HFA 90 mcg sulfate albuterol levalbuterol Respimat®
tartrate salmeterol xinafoate 2.5 mcg
Digihaler™ 90 mcg albuterol sulfate sulfate
inhalation powder
inhalation olodaterol
90 mcg albuterol
sulfate powder hydrochloride
albuterol
sulfate
inhalation
powder
ymptoms of coughing, wheezing or shortness of breath
ing of airway tissue; they do not relieve sudden s
TEROIDS reduce and prev
ent swell
C ORT I CO S
INHALED Asmanex® HFA Asmanex® Flovent® Diskus®
Arnuity Ellipta ® ® Flovent® HFA
50, 100, 200 mcg Twisthaler® 50, 100, 250 mcg
44, 110, Pulmicort
ArmonAir ®
50, 100, 200 mcg 110, 220 mcg
mometasone fluticasone
220 mcg Flexhaler® QVAR®
Alvesco® Digihaler™ fluticasone furoate inhalation furoate mometasone propionate
fluticasone Redihaler™
55, 113, 232 mcg
powder furoate inhalation 90, 180 mcg
HFA fluticasone inhalation powder propionate
budesonide 40, 80 mcg
80, 160 mcg propionate powder inhalation beclomethasone
ciclesonide inhalation powder dipropionate
powder
MUcSouC
contain both sho
gh, sp
pr odu
Long-actin g
short-acting mu
rt-acting beta
-a
scarinic anta 2 gonist and
gonist
NS
relieve Spiriva®
ing Spiriva® HandiHaler® Tudorza™ Pressair™
Short-act Incruse® Ellipta® 18 mcg Respimat® 400 mcg Combivent®
62.5 mcg tiotropium 1.25, 2.5 mcg aclidinium bromide Respimat®
Atrovent® HFA umeclidinium bromide tiotropium inhalation powder
20/100 mcg
17 mcg inhalation powder inhalation bromide
ipratropium ipratropium bromide
powder
bromide and albuterol
TIONS(LABA)
contain both long-acting beta -a
ElonDg-aIcCtinA
gon
and long-acting muscarinic an2 ta ist (LABA)
I N ATIO N M gonist (LAMA)
contain inh
al
long-acting ed corticosteroid,
COM B ed corticosteroid an d g beta2-agonist
Breo® Ellipta® Dulera ® Symbicort ® Wixela™ Inhub™ Anoro Ellipta
® ®
Bevespi
b
long-acting eta2 -agonist (LABA
muscarinic )a
both inhal
contain
AirDuo ®
50/5, 100/5, 80/4.5, 160/4.5 mcg 100/50, 250/50, 62.5/25 mcg Aerosphere®
Duaklir® antagonis nd
AirDuo® 100/25, 200/25 mcg 500/50 mcg Pressair® Stiolto™ t (LAMA)
Advair HFA
® RespiClick ®
200/5 mcg
budesonide and
umeclidinium and 9/4.8 mcg Respimat® Trelegy ®
Digihaler™ fluticasone furoate formoterol fumarate fluticasone propionate
Ellipta® Breztri
Advair Diskus ®
45/21, 115/21,
55/14, 113/14,
55/14, 113/14, and vilanterol mometasone furoate dihydrate and salmeterol xinafoate
vilanterol inhalation
powder
glycopyrrolate and 400, 12 mcg
2.5/2.5 mcg
100/50, 250/50, 230/21 mcg
232/14 mcg
232/14 mcg inhalation powder and formoterol (approved generic of formoterol fumarate aclidinium bromide tiotropium 200/62.5/25 mcg, Aerosphere™
500/50 mcg fluticasone fumarate dihydrate Advair Diskus) and formoterol 100/62.5/25 mcg
fluticasone
fluticasone propionate
bromide 160/9/4.8 mcg
propionate and propionate fumarate and olodaterol fluticasone furoate,
fluticasone propionate and salmeterol budesonide,
salmeterol and umeclidinium and glycopyrrolate and
and salmeterol inhalation
xinafoate salmeterol vilanterol inhalation formoterol fumarate
inhalation powder powder inhalation powder
powder
BRONCHIAL THERMOPLAST
athways that c
a use airway inflamm
ation; delivered by injection
or IV
Y PDE4 INHIBI
S T ORS
BIOLOGIC
and p
target cells Xolair® ease lung infla
Nucala ® Tezspire™ A minimally invasive procedure that
mmation an
d reduce exa
Fasenra™ mepolizumab
tezepelumab-ekko omalizumab
uses mild heat to reduce airway
cerbation
s
Dupixent ®
benralizumab
smooth muscle, leading to fewer Daliresp®
dupilumab
severe asthma flares, ER visits, 250, 500 mcg
Cinqair® and days lost from activities.
roflumilast
reslizumab www.btforasthma.com
Name: Birthdate:
Asthma Severity: Intermittent Mild Persistent Moderate Persistent Severe Persistent
He/she has had many or severe asthma attacks/exacerbations
Green Zone
J Have the child take these medicines every day, even when the child feels well.
Yellow Zone
Begin the sick treatment plan if the child has a cough, wheeze, shortness of breath, or tight chest. Have the
child take all of these medicines when sick.
Change:
If the child is in the yellow zone more than 24 hours or is getting worse, follow red zone and call the doctor right away!
Red Zone If breathing is hard and fast, ribs sticking out, trouble walking, talking, or sleeping.
Get Help Now
School Staff: Follow the Yellow and Red Zone plans for rescue medicines according to asthma symptoms.
Unless otherwise noted, the only controllers to be administered in school are those listed as “given in school” in the green zone.
Both the asthma provider and the parent feel that the child may carry and self-administer their inhalers
School nurse agrees with student self-administering the inhalers
Asthma Provider Printed Name and Contact Information: Asthma Provider Signature:
Date:
Parent/Guardian: I give written authorization for the medications listed in the action plan to be administered in school by the nurse or other school
members as appropriate. I consent to communication between the prescribing health care provider/clinic, the school nurse, the school medical advisor
and school-based health clinic providers necessary for asthma management and administration of this medication.
Parent/guardian signature: School Nurse Reviewed:
Date: Date: